Firm to offer a medical replace on the EDIT-301 Part 1/2 RUBY trial for SCD in June on the European Hematology Affiliation Congress (EHA) and in a Firm-sponsored webinar

On monitor to dose 20 complete sufferers by year-end within the RUBY trial

First affected person in EDIT-301 EDITHAL trial for TDT dosed with profitable neutrophil and platelet engraftment; Firm on monitor to offer medical replace by year-end

Appointed Emma Reeve as Chair of the Board, efficient at Annual Assembly of Stockholders, and Elliott Levy, M.D. as an Unbiased Director

CAMBRIDGE, Mass., Might 05, 2023 (GLOBE NEWSWIRE) — Editas Medication, Inc. (Nasdaq: EDIT), a medical stage genome enhancing firm, right this moment reported enterprise highlights and monetary outcomes for the primary quarter 2023.

“I’m energized by our sturdy begin to the 12 months. We entered 2023 with the target of accelerating the event of EDIT-301 and positioning Editas as a frontrunner in programable in vivo gene enhancing. Following on our December EDIT-301 medical knowledge displaying a aggressive and doubtlessly differentiated product, we now have constructed appreciable momentum with our EDIT-301 program, together with dosing and engraftment of the primary affected person in our EDITHAL trial. We look ahead to disclosing the medical progress of EDIT-301 after we present a RUBY trial replace with security and efficacy knowledge from a number of sufferers subsequent month in an oral presentation on the European Hematology Affiliation Congress and in a Firm-sponsored webinar. I’m happy with the progress we’ve made in opposition to our strategic plan,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Government Officer, Editas Medication. “Alongside our newly sharpened strategic focus are our world-class scientists and staff who’re dedicated to our strategic course and are constructing on the momentum from our medical milestones so far and driving execution in direction of our objectives.”

Current Achievements and Outlook

Ex Vivo Hemoglobinopathies

Story continues

Enterprise Growth & Different Company Highlights

• Enterprise Growth
  In January 2023, the Firm introduced that it had entered right into a definitive settlement with Shoreline Biosciences, Inc., underneath which Shoreline acquired Editas Medication’s preclinical gene edited induced pluripotent stem cell (iPSC) derived pure killer cell (iNK) applications, together with EDIT-202, and associated manufacturing applied sciences. Moreover, Shoreline licensed Editas Medication’s rights to proprietary SLEEK (Choice by Important-gene Exon Knock-in) and AsCas12a gene enhancing applied sciences.

• Management
  Emma Reeve appointed as Chair of the Editas Board of Administrators, efficient on the Firm’s annual stockholder assembly, scheduled for June 1
  Ms. Reeve joined the Editas Medication Board of Administrators in September 2021. Ms. Reeve is an completed biopharmaceutical government with greater than 25 years of world monetary expertise throughout pharmaceutical, medical machine, and biopharmaceutical firms.

  Elliott Levy, M.D., appointed to the Editas Board of Administrators as an impartial director
  Dr. Levy is an completed biopharmaceutical government with greater than 20 years of world analysis and growth experience, together with main medical technique and growth for a number of applications in any respect levels of growth at world biopharmaceutical firms Amgen and Bristol Myers Squibb.

  Linea Aspesi joined Editas as Chief Folks Officer
  Ms. Aspesi brings to Editas greater than 25 years expertise, together with 15 years within the life sciences sector, aligning expertise plans to firm imaginative and prescient, mission, and values, and partnering with senior leaders to outline and drive cultural transformation methods.

First Quarter 2023 Monetary Outcomes

Money, money equivalents, and marketable securities as of March 31, 2023, had been $401.8 million in comparison with $437.4 million as of December 31, 2022. The Firm expects present money, money equivalents and marketable securities to fund working bills and capital expenditures into 2025.

• For the three months ended March 31, 2023, web loss attributable to widespread stockholders was $49.0 million, or $0.71 per share, in comparison with web lack of $50.5 million, or $0.74 per share, for a similar interval in 2022.

• Collaboration and different analysis and growth revenues elevated by $3.1 million to $9.9 million for the three months ended March 31, 2023, in comparison with $6.8 million for a similar interval in 2022. The rise is expounded to the Firm’s sale of its wholly owned oncology property and associated licenses in January 2023.

• Analysis and growth bills had been flat at $37.8 million for the three months ended March 31, 2023, in comparison with $38.0 million for a similar interval in 2022.

• Normal and administrative bills elevated by $3.5 million to $23.0 million for the three months ended March 31, 2023, from $19.5 million for a similar interval in 2022. The rise was primarily attributable to elevated skilled providers bills to help enterprise growth actions, partially offset by a lower in inventory compensation expense.

Upcoming Occasions

Editas Medication plans to take part within the following scientific and medical convention:

• European Hematology Affiliation (EHA) 2023 Congress
  June 8-11, 2023, Frankfurt, Germany

Editas Medication plans to take part within the following investor occasions:

• Financial institution of America Securities 2023 Well being Care Convention
  Might September 11, 2023, Las Vegas, NV

• RBC Capital Markets International Healthcare Convention 2023
  Might 16, 2023, New York, NY

Convention Name
The Editas Medication administration crew will host a convention name and webcast right this moment at 8:00 a.m. ET to offer and talk about a company replace and monetary outcomes for the primary quarter of 2023. To entry the decision, please dial 1-877-407-0989 (home) or 1-201-389-0921 (worldwide) and ask for the Editas Medication earnings name. A dwell webcast of the decision may also be obtainable on the Traders part of the Editas Medication web site at www.editasmedicine.com, and a replay shall be obtainable roughly two hours after its completion.

About Editas Medication
As a medical stage genome enhancing firm, Editas Medication is targeted on translating the facility and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome enhancing methods into a strong pipeline of remedies for folks dwelling with critical ailments all over the world. Editas Medication goals to find, develop, manufacture, and commercialize transformative, sturdy, precision genomic medicines for a broad class of ailments. Editas Medication is the unique licensee of Broad Institute and Harvard College’s Cas9 patent estates and Broad Institute’s Cas12a patent property for human medicines. For the most recent info and scientific displays, please go to www.editasmedicine.com.

Ahead-Trying Statements
This press launch comprises forward-looking statements and data inside the that means of The Personal Securities Litigation Reform Act of 1995. The phrases ‘‘anticipate,’’ ‘‘imagine,’’ ‘‘proceed,’’ ‘‘might,’’ ‘‘estimate,’’ ‘‘anticipate,’’ ‘‘intend,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘venture,’’ ‘‘goal,’’ ‘‘ought to,’’ ‘‘would,’’ and comparable expressions are meant to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Ahead-looking statements on this press launch embrace statements concerning the initiation, timing, progress and outcomes of the Firm’s preclinical and medical research and its analysis and growth applications, together with dosing 20 complete sufferers by year-end within the RUBY trial, the timing for the Firm’s receipt and presentation of knowledge from its medical trials and preclinical research, together with a medical replace for the RUBY trial in June 2023 and a further medical replace by year-end and a medical replace from the EDITHAL trial by year-end, potential of, and expectations for, the Firm’s product candidates, the timing or chance of regulatory filings and approvals, and the Firm’s expectations concerning money runway. The Firm might not truly obtain the plans, intentions, or expectations disclosed in these forward-looking statements, and you shouldn’t place undue reliance on these forward-looking statements. Precise outcomes or occasions might differ materially from the plans, intentions and expectations disclosed in these forward-looking statements because of numerous essential elements, together with: uncertainties inherent within the initiation and completion of pre-clinical research and medical trials, together with the RUBY and EDITHAL trials, and medical growth of the Firm’s product candidates, together with EDIT-301; availability and timing of outcomes from pre-clinical research and medical trials; whether or not interim outcomes from a medical trial shall be predictive of the ultimate outcomes of the trial or the outcomes of future trials; expectations for regulatory approvals to conduct trials or to market merchandise and availability of funding enough for the Firm’s foreseeable and unforeseeable working bills and capital expenditure necessities. These and different dangers are described in larger element underneath the caption “Danger Components” included within the Firm’s most up-to-date Annual Report on Type 10-Okay, which is on file with the Securities and Change Fee, and in different filings that the Firm might make with the Securities and Change Fee sooner or later. Any forward-looking statements contained on this press launch symbolize the Firm’s views solely as of the date hereof and shouldn’t be relied upon as representing its views as of any subsequent date. Besides as required by regulation, the Firm explicitly disclaims any obligation to replace any forward-looking statements.

EDITAS MEDICINE, INC.
Consolidated Assertion of Operations
(quantities in hundreds, besides share and per share knowledge)
(Unaudited)

EDITAS MEDICINE, INC.
Chosen Consolidated Steadiness Sheet Objects
(quantities in hundreds)
(Unaudited)

CONTACT: Media and Investor Contact: Cristi Barnett (617) 401-0113 [email protected]